MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-023-42668-7

Медицинская библиотека · Nature communications · 2023

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.

Chiaro Jacopo, Antignani Gabriella, Feola Sara, Feodoroff Michaela, Martins Beatriz, Cojoc Hanne, Russo Salvatore, Fusciello Manlio, Hamdan Firas, Ferrari Valentina, Ciampi Daniele, Ilonen Ilkka, Räsänen Jari, Mäyränpää Mikko, Partanen Jukka, Koskela Satu, Honkanen Jarno, Halonen Jussi, Kuryk Lukasz, Rescigno Maria, Grönholm Mikaela, Branca Rui M, Lehtiö Janne, Cerullo Vincenzo

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel therapeutic strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vaccination. To date, research on mesothelioma has focused on the identification of molecular signatures to better classify and characterize the disease, and little is known about therapeutic targets that engage cytotoxic (CD8+) T cells. In this study we investigate the immunopeptidomic antigen-presented landscape of MPM in both murine (AB12 cell line) and human cell lines (H28, MSTO-211H, H2452, and JL1), as well as in patients' primary tumors. Applying state-of-the-art immuno-affinity purification methodologies, we identify MHC I-restricted peptides presented on the surface of malignant cells. We characterize in vitro the immunogenicity profile of the eluted peptides using T cells from human healthy donors and cancer patients. Furthermore, we use the most promising peptides to formulate an oncolytic virus-based precision immunotherapy (PeptiCRAd) and test its efficacy in a mouse model of mesothelioma in female mice. Overall, we demonstrate that the use of immunopeptidomic analysis in combination with oncolytic immunotherapy represents a feasible and effective strategy to tackle untreatable tumors.

Для цитирования: Chiaro Jacopo, Antignani Gabriella, Feola Sara, Feodoroff Michaela, Martins Beatriz, Cojoc Hanne, Russo Salvatore, Fusciello Manlio, Hamdan Firas, Ferrari Valentina, Ciampi Daniele, Ilonen Ilkka, Räsänen Jari, Mäyränpää Mikko, Partanen Jukka, Koskela Satu, Honkanen Jarno, Halonen Jussi, Kuryk Lukasz, Rescigno Maria, Grönholm Mikaela, Branca Rui M, Lehtiö Janne, Cerullo Vincenzo. Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.. Nature communications. 2023. DOI: 10.1038/s41467-023-42668-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.